Prolia (Denosumab) FAERS Safety Signals: What Women Need to Know

What Is Prolia and Why Do Women Use It?

Prolia (denosumab 60 mg every 6 months, subcutaneous) is a fully human monoclonal antibody that blocks RANK ligand, the protein that drives osteoclast activity. By silencing osteoclasts, it sharply reduces bone resorption. The FDA approved it on June 1, 2010 specifically for postmenopausal women at high fracture risk, for men with osteoporosis, and for bone loss caused by hormone ablation in cancer.

Women are the primary users. Osteoporosis affects an estimated 10.2 million Americans, 80% of whom are women, and denosumab's twice-yearly injection schedule makes adherence easier than daily oral bisphosphonates for many of them. The FREEDOM trial, the key phase 3 randomized controlled trial, enrolled 7,868 postmenopausal women aged 60-90 and showed a 68% relative risk reduction in new vertebral fractures and a 40% reduction in hip fractures over 3 years compared to placebo.

Because Prolia is prescribed almost exclusively in postmenopausal women (with narrower oncologic use in younger women), its entire safety profile is interpreted through a female hormonal lens. Understanding what the FDA's Adverse Event Reporting System (FAERS) shows, and what the current label says, helps you have a sharper conversation with your prescriber.

How FAERS Works and What It Can (and Cannot) Tell You

FAERS is the FDA's spontaneous reporting database. Anyone, patients, clinicians, pharmacists, manufacturers, can submit a report when a drug is suspected of causing harm. FAERS does not confirm causation. It detects signals: patterns where an adverse event occurs at a rate higher than expected compared to all other drugs in the database, measured by a statistic called the reporting odds ratio (ROR) or information component (IC).

The FDA also runs Sentinel, an active surveillance system that mines claims data from tens of millions of real patients. Sentinel is used to confirm or refute FAERS signals with actual denominator data.

For Prolia, FAERS has been generating signals since 2011. The FDA has responded with multiple label updates and Drug Safety Communications. The five signals reviewed below represent the strongest and most clinically actionable for women.

Signal 1: Hypocalcemia, Including Fatal Cases

Hypocalcemia is the most consistent and most serious FAERS signal for denosumab.

What the label says

The current Prolia prescribing information carries a Warnings and Precautions statement on hypocalcemia, calling it potentially severe and fatal. The FDA updated the label in 2012 and again in 2023 after ongoing FAERS case reviews identified fatal outcomes. The label now requires correction of hypocalcemia before initiating therapy and mandates monitoring of calcium levels, particularly in the first weeks after injection.

Why women are specifically at risk

Postmenopausal women have several intersecting vulnerabilities. Estrogen loss reduces intestinal calcium absorption efficiency. Many women in their 60s and 70s have subclinical vitamin D insufficiency; 41.6% of US adults over 60 have serum 25(OH)D below 50 nmol/L, and that prevalence is higher in women with limited sun exposure or darker skin. Denosumab dramatically increases calcium uptake into bone within hours of injection, a process sometimes called the "hungry bone" effect, and if dietary and supplement calcium are insufficient, serum calcium can drop precipitously.

Women with chronic kidney disease stage 4 or 5 are at highest risk. A 2021 pharmacovigilance study in Drug Safety analyzing FAERS through 2019 found denosumab was associated with a disproportionately high signal for hypocalcemia (ROR 23.4, 95% CI 21.1-26.0) compared to bisphosphonates, with cases concentrated in women with renal impairment.

Practical implication

Your clinician should check your serum calcium, albumin-corrected calcium, and 25(OH)D before every injection, not just the first one. The standard supplementation used in clinical practice is at least 1,000 mg elemental calcium daily and 800-1,000 IU vitamin D daily, though your individual needs may be higher.

Signal 2: Osteonecrosis of the Jaw (ONJ)

Osteonecrosis of the jaw (ONJ) involves exposed, necrotic bone in the jaw that fails to heal over 8 weeks in a patient without prior radiation to the jaw. Denosumab carries a Black Box-adjacent Warnings and Precautions statement for ONJ on the current label.

What FAERS and post-marketing data show

FAERS case series reviewed in a 2020 JAMA Internal Medicine analysis found the ROR for ONJ with denosumab to be significantly higher than with oral bisphosphonates in the osteoporosis indication, though absolute incidence in the osteoporosis population remains low at approximately 0.04% per year. Risk rises sharply with concomitant chemotherapy, corticosteroids, and angiogenesis inhibitors, which is relevant for women receiving denosumab for bone metastases at doses of 120 mg (Xgeva) rather than the 60 mg osteoporosis dose.

Women-specific considerations

Women treated for breast cancer frequently receive denosumab (as Xgeva 120 mg monthly) alongside aromatase inhibitors or CDK4/6 inhibitors, stacking risk factors. Dental procedures, tooth extractions in particular, are the most common precipitating events. The label recommends a dental exam before starting and avoidance of invasive dental procedures during treatment where possible.

For postmenopausal women taking Prolia at 60 mg every 6 months, absolute risk is low but not zero. Tell your dentist you are on denosumab before any procedure.

Signal 3: Atypical Femoral Fractures (AFF)

Atypical femoral fractures are stress fractures of the subtrochanteric or femoral shaft region that occur with minimal or no trauma, a paradox for a drug given to prevent fractures.

The FDA added AFF to the Prolia label in 2013 following accumulating FAERS reports and case series. Duration of use appears to be a risk factor; cases cluster in women who have been on antiresorptive therapy (bisphosphonates, denosumab, or a sequence of both) for more than 3-5 years.

A 2020 case series published in the Journal of Bone and Mineral Research identified 58 AFF cases associated with denosumab, nearly all in women, many of whom had previously used bisphosphonates. The prodromal symptom, aching thigh or groin pain weeks before complete fracture, is a critical warning sign. If you develop new thigh or groin pain while on Prolia, contact your prescriber promptly.

Signal 4: Serious Infections

Denosumab suppresses RANK ligand, which has immune functions beyond bone. RANK signaling participates in lymph node development and T-cell function. Post-marketing reports in FAERS have flagged serious infections, particularly skin infections (cellulitis and erysipelas), endocarditis, and urinary tract infections.

The FREEDOM trial found a statistically significant increase in skin infections in the denosumab arm: 1.3% vs. 0.4% in the placebo group. A 2022 pharmacoepidemiologic study in Annals of the Rheumatic Diseases using Sentinel-linked claims data confirmed elevated serious infection risk (hazard ratio 1.35, 95% CI 1.12-1.62) versus oral bisphosphonates.

Women with rheumatoid arthritis, diabetes, or on immunosuppressive therapy carry additional risk. If you develop any skin wound, redness, or fever after your injection, seek care early. The label instructs prescribers and patients to seek prompt medical attention for signs or symptoms of infection.

Signal 5: Rebound Vertebral Fractures After Stopping

This signal is arguably the most underappreciated risk specific to denosumab and disproportionately affects women who discontinue therapy without a clear transition plan.

The biology of rebound

Denosumab's effect on osteoclast suppression is reversible. Unlike bisphosphonates, which bind to bone matrix and continue working after the drug is stopped, denosumab clears from circulation over roughly 6 months. When it does, osteoclast activity rebounds sharply, sometimes above pre-treatment baseline, causing rapid bone mineral density loss and, critically, multiple simultaneous vertebral fractures.

What the data show

A 2017 study in Osteoporosis International found that among women who discontinued denosumab, those who did not transition to a bisphosphonate had vertebral fracture rates of up to 3.4% within 12-18 months of stopping. The fractures often occurred in clusters: two, three, or four vertebrae simultaneously, a pattern called "rebound-associated vertebral fractures." The FDA issued a Drug Safety Communication in 2022 reinforcing this risk.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis states directly: "After discontinuation of denosumab, antiresorptive therapy should be given to prevent rapid bone loss and rebound fractures."

A framework for women considering stopping Prolia

Women who want to stop denosumab need an individualized transition plan. The general approach used in clinical practice involves:

• Completing the planned denosumab course (typically at the 6-month injection interval).
• Starting a bisphosphonate (most commonly zoledronic acid 5 mg IV or alendronate 70 mg weekly) within 6 months of the last Prolia injection, ideally at month 6-7.
• Monitoring bone mineral density and bone turnover markers (specifically serum CTX) at 6-12 months post-transition.

Women who stopped denosumab to conceive, or who became pregnant unexpectedly, represent a special subgroup discussed below.

Pregnancy, Lactation, and Contraception: A Required and Critical Section

Prolia is contraindicated in pregnancy. This is not a relative contraindication. Animal studies show fetal harm at doses below the human clinical dose.

Pregnancy risk

The FDA label places denosumab in the category of drugs that cause fetal harm based on mechanism of action and animal data. In cynomolgus monkeys given denosumab at doses 0.1 times the human clinical dose (on an area-under-the-curve basis), offspring showed absent peripheral lymph nodes, abnormal bone growth, and decreased neonatal growth. No adequate and well-controlled studies exist in pregnant women. Given the mechanism (RANK/RANKL blockade is required for normal fetal lymph node and bone development), fetal harm in humans is biologically plausible.

RANK ligand signaling is required for normal mammary gland development during pregnancy and lactation, fetal bone modeling, and fetal lymphoid organogenesis. Exposing a fetus to denosumab could theoretically impair all three.

The ACOG Practice Bulletin on osteoporosis in women does not recommend denosumab in premenopausal women except in specific oncologic contexts with appropriate counseling, precisely because of this risk.

Reproductive-age women and denosumab

Prolia's primary indication is postmenopausal osteoporosis, so most users are not at risk of pregnancy. However, premenopausal women occasionally receive denosumab for:

• Glucocorticoid-induced osteoporosis.
• Bone metastases from breast or cervical cancer (as Xgeva 120 mg).
• Giant cell tumor of bone.
• Rare metabolic bone conditions.

Any woman of reproductive potential receiving denosumab must use highly effective contraception during treatment and for at least 5 months after the last dose. The label specifies this 5-month window based on denosumab's half-life. A combined hormonal contraceptive (pill, patch, or ring), a hormonal IUD, or a copper IUD are all acceptable options. Barrier methods alone are not adequate.

Lactation

Denosumab's transfer into human breast milk has not been studied. Given that the molecular weight of denosumab (approximately 147 kDa) is very large, meaningful transfer into mature breast milk is considered unlikely, but it has not been confirmed in human pharmacokinetic studies. Because of the potential for serious adverse effects in a nursing infant, the label advises against breastfeeding during treatment and for 5 months after the last dose. Women with postpartum osteoporosis (a rare but distinct condition) should discuss alternatives such as teriparatide with their clinician.

Pregnancy exposure registry

Amgen maintains a pregnancy exposure registry for women who become pregnant while on denosumab. Your clinician can enroll you. This kind of real-world data collection is how we eventually get human safety data where randomized trials are impossible.

Who This Drug Is Right For (and Who It Is Not)

Postmenopause: the primary candidate

Prolia is best suited for postmenopausal women who have:

• A T-score of -2.5 or below at the spine, hip, or femoral neck.
• A T-score between -1.0 and -2.5 with a 10-year FRAX fracture probability at or above 20% (major osteoporotic fracture) or 3% (hip fracture).
• A prior fragility fracture regardless of T-score.
• Renal impairment (CrCl 15-35 mL/min) where oral bisphosphonates are less reliably absorbed or not recommended.
• Intolerance to oral or IV bisphosphonates.

Perimenopause

Perimenopause is a period of accelerated bone loss. Women can lose 2-3% of bone mineral density per year in the 2 years before and after the final menstrual period. Denosumab is not typically initiated in perimenopause because the transition's timing is unpredictable, posing pregnancy risk, and because menopausal hormone therapy (MHT) is an effective bone-preserving option in this stage. If you are perimenopausal with low bone density, a discussion about MHT's skeletal benefits may be more appropriate than starting Prolia.

Trying to conceive or currently pregnant

Prolia is not appropriate. Period. If you are trying to conceive and have significant osteoporosis, discuss calcium and vitamin D optimization, weight-bearing exercise, and whether teriparatide (with its own pregnancy contraindication and washout) or MHT is appropriate for your situation. No antiresorptive drug is safe in pregnancy.

Women with PCOS

PCOS with anovulation may reduce peak bone mass in some women. Denosumab is not a first-line consideration for PCOS-related bone concerns; insulin sensitization, menstrual cycle regulation, and lifestyle are the primary interventions. Denosumab is not indicated in premenopausal women with PCOS unless a specific oncologic or metabolic bone indication exists.

Women post-breast-cancer treatment

Aromatase inhibitors (anastrozole, letrozole, exemestane) cause significant bone loss, reducing BMD by approximately 2-3% per year at the spine and hip in women with estrogen-deprivation. Denosumab at the osteoporosis dose (60 mg every 6 months) is an evidence-based option for these women. The 2021 ASCO/CCO guideline on bone health in cancer survivors recommends pharmacologic therapy including denosumab for women with T-score below -2.0 or -1.5 with additional risk factors while on aromatase inhibitor therapy.

The Evidence Gap: What We Don't Know in Women

The FREEDOM trial was conducted exclusively in postmenopausal women aged 60-90, which is appropriate for the indication. However, several gaps remain:

• No randomized data exist on denosumab use in premenopausal women with osteoporosis outside of oncologic contexts.
• Pharmacokinetic studies in women across different BMI ranges are limited. Obesity medicine data suggest higher adipose tissue volume may affect denosumab distribution, though the clinical significance at 60 mg every 6 months is not well characterized.
• Long-term data beyond 10 years (from the FREEDOM Extension) exist but are observational; the extension study followed only 4,550 of the original 7,868 participants through 10 years, and fracture data at that point lose placebo comparison.
• Women of Black and Hispanic backgrounds were underrepresented in FREEDOM. Black women have lower fracture risk per T-score unit than white women, meaning standard FRAX thresholds may be miscalibrated for them. Whether denosumab's fracture reduction magnitude is identical across racial groups is not definitively established.

When your clinician recommends Prolia, it is worth asking specifically which data apply to a woman with your age, ethnicity, comorbidities, and life stage.

Current FDA Label Status and Regulatory Timeline

The Prolia label has been updated multiple times since 2010. Key milestones:

• 2012: Hypocalcemia warnings strengthened after FAERS fatal case reports.
• 2013: Atypical femoral fracture added to Warnings and Precautions.
• 2014: Osteonecrosis of the jaw language expanded.
• 2020: Multiple vertebral fractures after discontinuation added explicitly to labeling.
• 2022: FDA Drug Safety Communication reinforcing rebound fracture risk issued.
• 2023: Label revision consolidating all current warnings; current version as of this article's publication.

The current full prescribing information is publicly available on FDA's Drugs@FDA database. You can read it. Patients are allowed to read drug labels, and reading yours is not excessive.

Monitoring Schedule Every Woman on Prolia Should Know

Before each injection (every 6 months):

• Serum calcium (albumin-corrected).
• Serum 25-hydroxyvitamin D (at least annually, more often if deficient).
• Review of any new dental procedures or jaw symptoms.
• Review of any new thigh or groin pain.
• Review of any new or worsening skin infections.

Annually:

• Bone mineral density (DEXA) every 1-2 years while on therapy.
• Serum creatinine and eGFR in women with known or suspected renal disease.

Before stopping:

• Discuss rebound fracture risk explicitly.
• Plan the bisphosphonate transition before the last injection, not after.

The Endocrine Society guidelines recommend against stopping denosumab without a written transition plan in women at high fracture risk.